PMID- 33360122
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2210-7762 (Print)
VI  - 252-253
DP  - 2021 Apr
TI  - RNA-Based next generation sequencing complements but does not replace 
      fluorescence in situ hybridization studies for the classification of aggressive 
      B-Cell lymphomas.
PG  - 43-47
LID - S2210-7762(20)30293-3 [pii]
LID - 10.1016/j.cancergen.2020.12.004 [doi]
AB  - Aggressive B-cell lymphomas are currently classified based in part upon the 
      presence or absence of translocations involving BCL2, BCL6, and MYC. Most 
      clinical laboratories employ fluorescence in situ hybridization (FISH) analysis 
      for the detection of these rearrangements. The potential role of RNA-based 
      sequencing approaches in the evaluation of malignant lymphoma is currently 
      unclear. In this study, we performed RNA sequencing (RNAseq) in 37 cases of 
      aggressive B-cell lymphomas using a commercially available next generation 
      sequencing assay and compared results to previously performed FISH studies. 
      RNAseq detected 1/7 MYC (14%), 3/8 BCL2 (38%) and 4/8 BCL6 (50%) translocations 
      identified by FISH. RNAseq also detected 1 MYC/IGH fusion in a case not initially 
      tested by FISH due to low MYC protein expression and 2 BCL6 translocations that 
      were not detected by FISH. RNAseq identified the partner gene in each detected 
      rearrangement, including a novel EIF4G1-BCL6 rearrangement. In summary, RNAseq 
      complements FISH for the detection of rearrangements of BCL2, BCL6 and MYC in the 
      evaluation and classification of aggressive B-cell lymphomas by detecting 
      rearrangements that may be cryptic by FISH methods and by identifying the 
      rearrangement partner genes. Detection of these clinically important 
      translocations may be optimized by combined use of FISH and RNAseq.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wang, Xiaoqiong
AU  - Wang X
AD  - Department of Laboratory Medicine, Robert J Tomsich Pathology and Laboratory 
      Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
FAU - Johnson, Verity
AU  - Johnson V
AD  - ArcherDx Inc, Boulder, CO, United States.
FAU - Johnson, Laura
AU  - Johnson L
AD  - ArcherDx Inc, Boulder, CO, United States.
FAU - Cook, James R
AU  - Cook JR
AD  - Department of Laboratory Medicine, Robert J Tomsich Pathology and Laboratory 
      Medicine Institute, Cleveland Clinic, Cleveland, OH, United States. Electronic 
      address: cookj2@ccf.org.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Female
MH  - High-Throughput Nucleotide Sequencing/*methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lymphoma, B-Cell/*classification/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Young Adult
OTO - NOTNLM
OT  - Lymphoma
OT  - MYC
OT  - Next generation sequencing
OT  - RNAseq
OT  - Translocation
EDAT- 2020/12/29 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/12/28 11:04
PHST- 2020/08/27 00:00 [received]
PHST- 2020/10/22 00:00 [revised]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/12/28 11:04 [entrez]
AID - S2210-7762(20)30293-3 [pii]
AID - 10.1016/j.cancergen.2020.12.004 [doi]
PST - ppublish
SO  - Cancer Genet. 2021 Apr;252-253:43-47. doi: 10.1016/j.cancergen.2020.12.004. Epub 
      2020 Dec 10.